Bank of America’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Bank of America’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-68,190	Closed	-$17.4K	–	8188
2023 Q1	$17.4K	Buy	68,190 +18,861	+38%	+$17K	﹤0.01%	6789
2022 Q4	$58.2K	Buy	49,329 +43,055	+686%	+$90.5K	﹤0.01%	6425
2022 Q3	$13K	Buy	6,274 +6,266	+78,325%	+$10.6K	﹤0.01%	7176
2022 Q2	$0	Sell	8 -23,345	-100%	-$91.3K	﹤0.01%	8657
2022 Q1	$118K	Buy	+23,353	New	+$106K	﹤0.01%	6771
2021 Q4	–	Sell	-61,132	Closed	-$608K	–	8868
2021 Q3	$608K	Hold	61,132	–	–	﹤0.01%	5494
2021 Q2	$604K	Buy	+61,132	New	+$599K	﹤0.01%	5276

Bank of America's PEAR Position: Q2 2023 in Review

Bank of America sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 68,190 shares — an estimated $17.4K sold.

Bank of America first reported a position in PEAR in Q2 2021 and held it in 7 quarters. The position peaked at $608K in Q3 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Bank of America reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Bank of America sold 68,190 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $17.4K.
Bank of America first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 7 quarters.
Bank of America's Pear Therapeutics, Inc. Class A Common Stock position peaked at $608K in Q3 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Bank of America's 13F filing for Q2 2023, filed 14 Aug 2023.